Top

Published in:

01-09-2015 | Gastrointestinal Oncology

Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)

Authors: Jordi Rubió-Casadevall, MD, Javier Martinez-Trufero, MD, Xabier Garcia-Albeniz, MD, Silvia Calabuig, MD, Antonio Lopez-Pousa, MD, Javier Garcia del Muro, MD, Joaquin Fra, MD, Andrés Redondo, MD, Nuria Lainez, MD, Andrés Poveda, MD, Claudia Valverde, MD, Ana De Juan, MD, Isabel Sevilla, MD, Antonio Casado, MD, Raquel Andres, MD, Josefina Cruz, MD, Javier Martin-Broto, MD, Joan Maurel, MD, the Spanish Group for Research on Sarcoma (GEIS)

Published in: Annals of Surgical Oncology | Issue 9/2015

Abstract

Background

Recurrent, metastatic, and locally advanced gastrointestinal stromal tumors (GISTs) can be treated successfully with imatinib mesylate. Surgery for residual disease has been suggested for nonrefractory metastatic GISTs to reduce the probability of resistant recurrent clones, although no randomized Phase III trial has been performed to answer the question about its benefit. We carried out an analysis of the outcome of patients with recurrent unresectable locally advanced or metastatic imatinib-sensitive priamary GIST in 14 institutions in Spain. We compared two cohorts: treated or not treated with surgery after partial response or stabilization by imatinib.

Patients and Methods

Data were obtained from the online GIST registry of the Spanish Group for Research in Sarcomas. Selected patients were then divided into two groups: group A, treated initially only with imatinib, and group B, treated additionally with metastasectomy. Baseline characteristics between groups were compared, and univariate and multivariate analysis for progression-free survival and overall survival (OS) were performed.

Results

Analysis was undertaken in 171 patients considered nonrefractory to imatinib. The median follow-up time was 56.6 months. Focusing on OS, the Eastern Cooperative Oncology Group performance status different than 0, extent of disease limited to one metastatic organ, and comparison between groups A or B achieved statistical difference in the multivariate analysis. Median survival was 59.9 months in group A and 87.6 months in group B.

Conclusions

Based in its benefit in OS, our study supports surgery of metastatic disease in GIST patients who respond to imatinib therapy.

Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course and prognostication in the pre-imatinib mesylate era: a population based study in western Sweden. Cancer. 2005;103(4):821–9.PubMedCrossRef

Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.PubMedCrossRef

Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–10PubMedCrossRef

Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing kit. J Clin Oncol. 2008;26:620–5.PubMedCrossRef

Green S, Weiss GR. Southwest Oncology Group standard response criteria, end point definitions, and toxicity criteria. Invest New Drugs. 1992;10:239–53PubMedCrossRef

Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–32.PubMedCrossRef

Blay JY, Le CA, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107–13.PubMedCrossRef

Lux ML, Rubin BP, Biase TL, et al. Kit extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000;156(3):791–5.PubMedCentralPubMedCrossRef

Heinrich MC, Owzar K, Corles CL, et al. Correlation of kinase genotype and clinical outcome in the North American intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26:5360–7.PubMedCentralPubMedCrossRef

10.

Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary kit mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res. 2006;12(6):1743–9.PubMedCrossRef

11.

Debiec- Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 2005;128(2):270–9.PubMedCrossRef

12.

Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005;23:5795–804.PubMedCrossRef

13.

Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg. 2007;245:341–6.PubMedCentralPubMedCrossRef

14.

DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg. 2007;245:347–52.PubMedCentralPubMedCrossRef

15.

Bauer S, Hartmann JT, de Wit M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer. 2005;117:316–25PubMedCrossRef

16.

Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14:14–24.PubMedCrossRef

17.

Bonvalot S, Eldweny H, Péchoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol. 2006;13(12):1596–603.PubMedCrossRef

18.

Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325–31PubMedCrossRef

19.

Mussi C, Ronellenfitsch U, Jakib J, et al Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol. 2010;21:403–8PubMedCrossRef

20.

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef

21.

Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.PubMedCrossRef

22.

Bauer S, Rutkowski P, Hohenberger P, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib: analysis of prognostic factors (EORTC–STBSG collaborative study). Eur J Surg Oncol. 2014;40(4):412–9.PubMedCrossRef

Title: Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)
Authors: Jordi Rubió-Casadevall, MD
Javier Martinez-Trufero, MD
Xabier Garcia-Albeniz, MD
Silvia Calabuig, MD
Antonio Lopez-Pousa, MD
Javier Garcia del Muro, MD
Joaquin Fra, MD
Andrés Redondo, MD
Nuria Lainez, MD
Andrés Poveda, MD
Claudia Valverde, MD
Ana De Juan, MD
Isabel Sevilla, MD
Antonio Casado, MD
Raquel Andres, MD
Josefina Cruz, MD
Javier Martin-Broto, MD
Joan Maurel, MD
the Spanish Group for Research on Sarcoma (GEIS)
Publication date: 01-09-2015
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 9/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-4360-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS)

Abstract

Background

Patients and Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2015

TREM-1, an Inflammatory Modulator, is Expressed in Hepatocellular Carcinoma Cells and Significantly Promotes Tumor Progression

Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study

Factors Affecting Cytokine Change After Esophagectomy for Esophageal Cancer

Quality of Life, Functional Outcomes, and Wound Complications in Patients with Soft Tissue Sarcomas Treated with Preoperative Chemoradiation: A Prospective Study

Chemotherapy for Patients with Colorectal Liver Metastases Who Underwent Curative Resection Improves Long-Term Outcomes: Systematic Review and Meta-analysis

Identification, Clinical Significance, and Management of Very Small Melanoma Metastases in Sentinel Lymph Nodes